Successful multidisciplinary therapy for a patient with liver metastasis from ascending colon adenocarcinoma: A case report and review of literature

BACKGROUND Liver metastasis is the most common form of distant metastasis in colorectal cancer, and the only possible curative treatment for patients with colorectal liver metastases (CRLM) is hepatectomy. However, approximately 25% of patients with CRLM have indications for liver resection at the initial diagnosis. Strategies aimed at downstaging large or multifocal tumors to enable curative resection are appealing. CASE SUMMARY A 42-year-old man was diagnosed with ascending colon cancer and liver metastases. Due to the huge lesion size and compression of the right portal vein, the liver metastases were initially diagnosed as unresectable lesions. The patient was treated with preoperative transcatheter arterial chemoembolization (TACE) consisting of 5-fluorouracil/Leucovorin/oxaliplatin/Endostar®. After four courses, radical right-sided colectomy and ileum transverse colon anastomosis were performed. Postoperatively, the pathological analysis revealed moderately differentiated adenocarcinoma with necrosis and negative margins. Thereafter, S7/S8 partial hepatectomy was performed after two courses of neoadjuvant chemotherapy. Pathological examination of the resected specimen revealed a pathologically complete response (pCR). Intrahepatic recurrence was detected more than two months after the operation, and the patient was then treated with TACE consisting of irinotecan/Leucovorin/fluorouracil therapy plus Endostar®. Subsequently, the patient was treated with a γ-knife to enhance local control. Notably, a pCR was reached, and the patient's overall survival time was > 9 years. CONCLUSION Multidisciplinary treatment can promote the conversion of initially unresectable colorectal liver metastasis and facilitate complete pathological remission of liver lesions.

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  P. Lai,et al.  Comparison of long-term survival outcome after curative hepatectomy between selected non-colorectal and colorectal liver metastases patients: A propensity score matching analysis. , 2020, Asian journal of surgery.

[3]  F. Arias,et al.  Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters , 2020, Clinical and Translational Oncology.

[4]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[5]  M. Bartels,et al.  Current Treatment of Colorectal Liver Metastasis as a Chronic Disease , 2019, AntiCancer Research.

[6]  A. Terahara,et al.  [Five-Year Local Control by Stereotactic Body Radiation Therapy(SBRT)for Liver Metastasis from Colorectal Cancer-A Case Report]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  M. Ychou,et al.  Two‐stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second‐stage completion and longer survival☆ , 2019, Surgery.

[8]  Y. Liu,et al.  Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model , 2018, Scientific Reports.

[9]  W. Ceelen,et al.  The impact of surgical resection of the primary tumor on the development of synchronous colorectal liver metastasis: a systematic review , 2018, Acta chirurgica Belgica.

[10]  D. Richel,et al.  Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis , 2018, CardioVascular and Interventional Radiology.

[11]  D. Levi,et al.  A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases , 2018, Chemotherapy.

[12]  S. Truant,et al.  Repeated Resections of Hepatic and Pulmonary Metastases from Colorectal Cancer Provide Long-Term Survival , 2018, World Journal of Surgery.

[13]  Jong Hoon Kim,et al.  Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. , 2017, International journal of radiation oncology, biology, physics.

[14]  L. Qin,et al.  Recombined human endostatin (Endostar) enhances cisplatin delivery and potentiates chemotherapy by decompressing colorectal cancer vessels. , 2017, International journal of clinical and experimental pathology.

[15]  Jeffrey W. Clark,et al.  Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases , 2017, Journal of Gastrointestinal Surgery.

[16]  W. Chapman,et al.  Time-to-Surgery and Survival Outcomes in Resectable Colorectal Liver Metastases: A Multi-Institutional Evaluation. , 2016, Journal of the American College of Surgeons.

[17]  Chong Zhao,et al.  The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma , 2015, Oncotarget.

[18]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Yin Zhang,et al.  Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study , 2015, Journal of chemotherapy.

[20]  H. Ohdan,et al.  Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis. , 2015, World journal of gastroenterology.

[21]  S. Zhang,et al.  Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial , 2015, Cancer Chemotherapy and Pharmacology.

[22]  D. Malka,et al.  Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases. , 2014, Journal of visceral surgery.

[23]  V. Catalano,et al.  Chemoembolization in colorectal liver metastases: the rebirth. , 2014, Anticancer research.

[24]  K. Muro,et al.  A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients , 2013, Japanese journal of clinical oncology.

[25]  Yutong He,et al.  Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer , 2011, Pathology & Oncology Research.

[26]  F. Saliba,et al.  Impact of Expanding Criteria for Resectability of Colorectal Metastases on Short- and Long-Term Outcomes After Hepatic Resection , 2011, Annals of surgery.

[27]  Yang Zhang,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Thomas Seufferlein,et al.  Targeted treatments in colorectal cancer: state of the art and future perspectives , 2010, Gut.

[29]  Rong-cheng Luo,et al.  [Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer]. , 2010, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[30]  Pornpimol Charoentong,et al.  Coordination of intratumoral immune reaction and human colorectal cancer recurrence. , 2009, Cancer research.

[31]  Y. Guan,et al.  Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. , 2007, World journal of gastroenterology.

[32]  Na Lu,et al.  Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. , 2007, Biochemical and biophysical research communications.

[33]  D. Mavroudis,et al.  Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study , 2007, BMC Cancer.

[34]  J. Folkman,et al.  Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. , 2006, Experimental cell research.

[35]  Robert D Timmerman,et al.  A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. , 2005, International journal of radiation oncology, biology, physics.

[36]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[37]  Zhigang Zhang,et al.  Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[38]  Xin-en Huang,et al.  Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[39]  C. von Kalle,et al.  Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794] , 2008, BMC Cancer.

[40]  M. P. Tristan D. Yan BSc,et al.  Systematic Review on Safety and Efficacy of Repeat Hepatectomy for Recurrent Liver Metastases from Colorectal Carcinoma , 2007, Annals of Surgical Oncology.